Tempus AI, Inc. (NASDAQ:TEM) EVP Andrew Polovin Sells 1,130 Shares

Tempus AI, Inc. (NASDAQ:TEM - Get Free Report) EVP Andrew Polovin sold 1,130 shares of the stock in a transaction that occurred on Monday, December 16th. The stock was sold at an average price of $40.23, for a total value of $45,459.90. Following the completion of the transaction, the executive vice president now owns 244,955 shares in the company, valued at $9,854,539.65. This represents a 0.46 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Andrew Polovin also recently made the following trade(s):

• On Wednesday, December 11th, Andrew Polovin sold 51,504 shares of Tempus AI stock. The stock was sold at an average price of $42.39, for a total transaction of $2,183,254.56.

Tempus AI Stock Down 12.0 %

Shares of TEM traded down $4.66 during mid-day trading on Wednesday, hitting $34.29. The company's stock had a trading volume of 7,396,915 shares, compared to its average volume of 1,521,735. Tempus AI, Inc. has a one year low of $22.89 and a one year high of $79.49. The company has a current ratio of 2.69, a quick ratio of 2.55 and a debt-to-equity ratio of 8.17. The business has a 50-day moving average of $52.24.

Institutional Trading of Tempus AI

Institutional investors have recently modified their holdings of the company. First Horizon Advisors Inc. acquired a new position in shares of Tempus AI in the third quarter valued at $30,000. Vestor Capital LLC bought a new stake in Tempus AI in the 3rd quarter valued at $153,000. Stifel Financial Corp bought a new stake in Tempus AI in the 3rd quarter valued at $218,000. Sandia Investment Management LP acquired a new position in shares of Tempus AI in the 2nd quarter valued at $136,000. Finally, IQ EQ FUND MANAGEMENT IRELAND Ltd bought a new position in shares of Tempus AI during the 3rd quarter worth about $258,000. Institutional investors and hedge funds own 24.22% of the company's stock.

Wall Street Analysts Forecast Growth

A number of research analysts have recently weighed in on the stock. Bank of America raised their price target on shares of Tempus AI from $52.00 to $54.00 and gave the company a "neutral" rating in a report on Friday, December 13th. Guggenheim assumed coverage on Tempus AI in a research report on Monday, December 9th. They issued a "buy" rating and a $74.00 price target for the company. Stifel Nicolaus downgraded Tempus AI from a "buy" rating to a "hold" rating and upped their price target for the stock from $45.00 to $65.00 in a research note on Monday, November 11th. Wolfe Research began coverage on Tempus AI in a report on Friday, December 13th. They issued an "outperform" rating and a $60.00 target price for the company. Finally, Piper Sandler reiterated a "neutral" rating and set a $70.00 price target (up previously from $40.00) on shares of Tempus AI in a report on Tuesday, November 12th. Three investment analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average target price of $56.00.

About Tempus AI

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.